Fibromyalgia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Fibromyalgia - Pipeline Review, H2 2016

Fibromyalgia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Fibromyalgia - Pipeline Review, H2 2016
Published Jul 20, 2016
80 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Fibromyalgia - Pipeline Review, H2 2016, provides an overview of the Fibromyalgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fibromyalgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fibromyalgia
- The report reviews pipeline therapeutics for Fibromyalgia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Fibromyalgia therapeutics and enlists all their major and minor projects
- The report assesses Fibromyalgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Fibromyalgia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Fibromyalgia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing

  
Source:
Document ID
GMDHC8279IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Fibromyalgia Overview81
Therapeutics Development92
  Pipeline Products for Fibromyalgia Overview91
  Pipeline Products for Fibromyalgia Comparative Analysis101
Fibromyalgia Therapeutics under Development by Companies111
Fibromyalgia Therapeutics under Investigation by Universities/Institutes121
Fibromyalgia Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Fibromyalgia Products under Development by Companies161
Fibromyalgia Products under Investigation by Universities/Institutes171
Fibromyalgia Companies Involved in Therapeutics Development187
  Astellas Pharma Inc.181
  Daiichi Sankyo Company, Limited191
  Merck &Co., Inc.201
  SWITCH Biotech LLC211
  Theravance Biopharma, Inc.221
  Tonix Pharmaceuticals Holding Corp.231
  Zynerba Pharmaceuticals, Inc.241
Fibromyalgia Therapeutics Assessment2510
  Assessment by Monotherapy Products251
  Assessment by Combination Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration312
  Assessment by Molecule Type332
Drug Profiles3528
  (celecoxib + famciclovir) Drug Profile351
  AS-1069562 Drug Profile361
  ASP-0819 Drug Profile371
  ASP-8062 Drug Profile381
  AXIBU-04 Drug Profile391
  mirogabalin besylate Drug Profile402
  mirtazapine ODT Drug Profile421
  naltrexone hydrochloride Drug Profile433
  Peptide to Block Voltage-Dependent N-Type Calcium Channel for Cancer Pain, Fibromyalgia, Inflammatory Pain and Neuropathic Pain Drug Profile461
  Small Molecules for Fibromyalgia Drug Profile471
  SWT-06101 Drug Profile481
  TD-9855 Drug Profile492
  TNX-102 Drug Profile518
  U-2902 Drug Profile592
  ZYN-001 Drug Profile612
Fibromyalgia Dormant Projects633
Fibromyalgia Discontinued Products661
Fibromyalgia Product Development Milestones6712
  Featured News &Press Releases671
    Jun 09, 2016: Tonix Pharmaceuticals Presents at EULAR Results of a Retrospective Analysis from the Phase 2b BESTFIT Clinical Study of TNX-102 SL in Fibromyalgia671
    Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention681
    May 02, 2016: Tonix Pharmaceuticals Completes Enrollment in Phase 3 Clinical Trial of TNX-102 SL in Fibromyalgia681
    Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting691
    Jan 28, 2016: Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia691
    Nov 10, 2015: Tonix Pharmaceuticals Presents Additional Data on Tonmya Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia at 2015 ACR/ARHP Annual Meeting701
    Oct 01, 2015: Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting711
    Jun 17, 2015: Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya as Proposed Brand Name for Cyclobenzaprine HCl Sublingual Tablets, 2.8 mg721
    Jun 11, 2015: Tonix Pharmaceuticals Presents Additional Data From Phase 2b BESTFIT Clinical Study at EULAR722
    May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR741
    May 20, 2015: Tonix Pharmaceuticals to Present Additional Data From Completed Phase 2b Study of TNX-102 SL in Fibromyalgia at EULAR751
    May 13, 2015: Tonix Pharmaceuticals Launches Phase 3 Clinical Study of TNX-102 SL in Fibromyalgia751
    Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin761
    Jan 06, 2015: Tonix Pharmaceuticals Provides Clinical and Regulatory Update on its Continued Development of TNX-102 SL in Fibromyalgia771
    Nov 18, 2014: Novel Fibromyalgia Treatment Shows Promise In Study772
Appendix792
  Methodology791
  Coverage791
  Secondary Research791
  Primary Research791
  Expert Panel Validation791
  Contact Us791
  Disclaimer801

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Fibromyalgia - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Fibromyalgia-Pipeline-Review-H2-2016-2088-16244>
  
APA:
Global Markets Direct - Market Research. (2016). Fibromyalgia - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Fibromyalgia-Pipeline-Review-H2-2016-2088-16244>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.